Evidence map›Paper›PMID 33327360›Full record

Observational studyMedicine2020

Investigation of the interaction between proton pump inhibitors and clopidogrel using VerifyNow P2Y12 assay.

Sheng-Feng Lin, Pei-Chin Lin, Chih-Chun Chang, Wei-Lun Chang, Fang-Yeh Chu

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Sheng-Feng LinSchool of Public Health, College of Public Health, Taipei Medical University, Taipei.
Pei-Chin LinDepartment of Clinical Pathology, Far Eastern Memorial Hospital.
Chih-Chun ChangDepartment of Clinical Pathology, Far Eastern Memorial Hospital.
Wei-Lun ChangDepartment of Pharmacy, Far Eastern Memorial Hospital, New Taipei.
Fang-Yeh ChuDepartment of Clinical Pathology, Far Eastern Memorial Hospital.ORCID 0000-0002-9064-6889
Far Eastern Memorial Hospital · TWApple (Israel) · ILYuanpei University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRandomized trials and observation studies have revealed conflicting results regarding the interaction between clopidogrel and proton pump inhibitors (PPIs). The aim of our study was to provide laboratory evidence regarding whether PPIs blunt the antiplatelet reactivity of clopidogrel.

methodsWe included records of Asian patients who received clopidogrel treatment for cardiovascular or cerebrovascular events and the VerifyNow P2Y12 assay for platelet reactivity monitoring. The responsiveness of antiplatelet effect to clopidogrel was analyzed according to 3 criteria:Results: Patients treated without PPIs did not differ significantly from those concomitantly treated with PPIs in terms of levels of PI (25.7% ± 24.3% vs 23.0 ± 25.3%, P = .4315), PRU (187.3 ± 74.0 vs 197.4 ± 77.3, P = .3373), or responsiveness to antiplatelet (adjusted absolute risk, 3.5%; 95% confidence interval, - 10.7 to 17.7%; P = .6297). Patients treated with lansoprazole, esomeprazole, pantoprazole, and rabeprazole exhibited no significant differences in PRU or PI levels compared with those treated without PPIs. By contrast, patients treated with dexlansoprazole exhibited a significantly decreased level of PI (25.7% ± 24.3% vs 14.0% ± 21.6%, P = .0297) and responsiveness to clopidogrel under the criterion PI > 20% (adjusted absolute risk: 10.5%; 95% confidence interval: 2.6% to 43.6%; P = .0274).

conclusionNo robust interaction between clopidogrel and PPIs was found, but caution should be exercised in the concomitant use of dexlansoprazole and clopidogrel in Asians.

Indexed as

AgedAged, 80 and overAge FactorsAsian PeopleClopidogrelComorbidityDrug InteractionsFemaleHumansMaleMiddle AgedPlatelet AggregationPlatelet Aggregation InhibitorsProton Pump InhibitorsReceptors, Purinergic P2Y12Sex FactorsClopidogrelP2RY12 protein, humanPlatelet Aggregation InhibitorsProton Pump InhibitorsReceptors, Purinergic P2Y12

Identifiers

PMID33327360
PMCPMC7738015
OpenAlexW3112563832

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.